+

WO1998031369A1 - Preparations a usage externe a absorption percutanee - Google Patents

Preparations a usage externe a absorption percutanee Download PDF

Info

Publication number
WO1998031369A1
WO1998031369A1 PCT/JP1998/000123 JP9800123W WO9831369A1 WO 1998031369 A1 WO1998031369 A1 WO 1998031369A1 JP 9800123 W JP9800123 W JP 9800123W WO 9831369 A1 WO9831369 A1 WO 9831369A1
Authority
WO
WIPO (PCT)
Prior art keywords
external preparation
sensitive adhesive
pressure
acid
transdermal absorption
Prior art date
Application number
PCT/JP1998/000123
Other languages
English (en)
Japanese (ja)
Inventor
Kazushi Ito
Tadao Kawamori
Masanori Matsuda
Kiyoshi Kuriyama
Original Assignee
Sekisui Chemical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sekisui Chemical Co., Ltd. filed Critical Sekisui Chemical Co., Ltd.
Priority to AU54957/98A priority Critical patent/AU5495798A/en
Publication of WO1998031369A1 publication Critical patent/WO1998031369A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Definitions

  • the present invention relates to an external preparation for percutaneous absorption, and more particularly to a topical external preparation having a systemic therapeutic effect for the treatment of chronic inflammatory diseases such as autoimmune diseases (eg, rheumatoid arthritis) or cancer diseases such as leukemia.
  • chronic inflammatory diseases such as autoimmune diseases (eg, rheumatoid arthritis) or cancer diseases such as leukemia.
  • agent eg, rheumatoid arthritis
  • Methotrexate has been used as an antineoplastic drug in the form of tablets and injections for diseases such as acute leukemia, chronic myeloid leukemia, and villous disease. In recent years, administration as an immunosuppressant for chronic articular rheumatism has also been attempted (Pharmaceutical Journal, Vol. 27, No. 3, p544-25447, 1999). 1 year). Also, JP-A-63-27432 discloses a preparation comprising methotrexate or an analog thereof, a skin-penetrating reagent and a carrier, for example, a hyperproliferative epithelial disease such as psoriasis. It is disclosed that a therapeutic effect is produced by local administration to the skin. It has also recently been shown to be highly effective against breast cancer (Cancer and Chemotherapy, Vol. 21, No. 12, pl 949, 1994).
  • An object of the present invention is to reduce the above-mentioned side effects of methotrexate and to improve the patient's compliance and quality of life.
  • chronic inflammatory diseases such as autoimmune diseases (for example, chronic)
  • the present invention relates to an external preparation for percutaneous absorption comprising a drug in a base and having a systemic therapeutic effect on a disease to be treated, wherein the drug is methotrexate.
  • Agent BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 is a schematic diagram for explaining a rat skin permeability test using a diffusion cell in Test Example 6.
  • 1 represents a diffusion cell.
  • 2 represents one receptor tank.
  • 3 represents a donor tank.
  • 4 represents an opening.
  • 5 represents a flange.
  • 6 represents a flange.
  • 7 indicates the sampling port.
  • 8 represents a piece of skin.
  • 9 represents a magnetic stirrer.
  • the external preparation for transdermal absorption of the present invention contains a drug in a base.
  • the drug is methotrexate.
  • the external preparation for transdermal absorption of the present invention uses methotrexate as a form of the external preparation for transdermal absorption, not the conventional form of tablets or injections.
  • methotrexate as a form of the external preparation for transdermal absorption, not the conventional form of tablets or injections.
  • the effect of maintaining the blood concentration can be maintained, which not only reduces the number of administrations of the drug but also simplifies the administration and allows patients to withstand long-term administration.
  • improvements in patient compliance and quality of life are achieved.
  • the blood concentration of methotrexate can be controlled without temporarily increasing the blood concentration, hepatic metabolism can be particularly avoided. You.
  • it is administered parenterally its effects on the digestive tract are reduced, especially when compared to tablets.
  • the content of the above-mentioned methotrexate in the base is preferably 0.001 to 30% by weight. If the amount is too small, the transdermal absorption of turaxate will be insufficient, so that effective drug efficacy may not be exhibited. If the amount is too large, the amount of transdermal absorption will be too large, which may cause side effects. is there. More preferably, it is from 0.001 to 20% by weight, and even more preferably from 0.005 to 15% by weight.
  • the base is not particularly limited as long as it is pharmaceutically acceptable.
  • polymers, inorganic fillers, oils and fats, hydrocarbons, polyhydric alcohols, higher fatty acids, higher alcohols, lower alcohols Alcohol and water are preferably used. These may be used alone or in combination of two or more. Further, a composition containing these may be used.
  • the polymer is not particularly limited, and examples thereof include sodium alginate, gelatin, corn starch, tragacanth, methylcellulose, hydroxyshethyl cellulose, hydroquinine propylcellulose, carboquin methylcellulose, sodium propyloxymethylcellulose, and dextrin. , Carboxymethyl starch, polyvinyl alcohol, polyacrylic acid, polyacrylate (eg, sodium salt), meth- oxyethylene-maleic anhydride copolymer, polyvinyl ether, polyvinylpyrrolidone, polyacrylamide and the like.
  • the inorganic filler is not particularly restricted but includes, for example, colloidal hydrous aluminum silicates such as kaolin and bentonite; colloidal hydrous magnesium silicates such as veegum; aluminum-based minerals; titanium oxide; Zinc, gay acid and the like.
  • the fats and oils are not particularly limited, and include, for example, beeswax, olive oil, cocoa oil, sesame oil, soybean oil, camellia oil, laccase oil, beef oil, pork oil, lanolin and the like.
  • the hydrocarbon is not particularly limited, and includes, for example, white petrolatum, paraffin, liquid paraffin, hide mouth carbon gel ointment (for example, “Plastibase” (manufactured by Bristol-Myers Squibb)) and the like.
  • the polyhydric alcohol is not particularly limited, and includes, for example, ethylene glycol, polyethylene glycol, propylene glycol, polypropylene glycol, sorbitol and the like.
  • the higher fatty acid is not particularly limited, and includes, for example, pupuric acid, nonanoic acid, puprilic acid, pendecylic acid, lauric acid, tridecylic acid, myristic acid, pentadecylic acid, lumitic acid, heptadecylic acid, stearic acid, Saturated or unsaturated fatty acids such as oleic acid, nonadenic acid, arachidonic acid, linoleic acid, behenic acid, lignoceric acid, cerotic acid, hebutacosanoic acid, palmitoleic acid, vaccenic acid, and linolenic acid.
  • the higher alcohol is not particularly limited. Examples thereof include lauryl alcohol, dodecyl alcohol, myristyl alcohol, pentadecyl alcohol, cetyl alcohol, hexadecyl alcohol, heptadecyl alcohol, stearyl alcohol, oleyl alcohol, and nona. Decyl alcohol, eicosyl alcohol, ceryl alcohol, mesyl alcohol, cetyl alcohol and the like.
  • the lower alcohol is not particularly limited, and includes, for example, isopropyl alcohol, ethanol and the like.
  • the base preferably contains a transdermal absorption enhancer.
  • the above-mentioned percutaneous absorption enhancer is not particularly limited as long as it is usually used in a percutaneous absorption preparation.
  • alcohols, organic acids, higher fatty acid esters, and hydroxycarboxylic acid esters are used.
  • N-acyl sarcosine and a surfactant are preferably used. These may be used alone or in combination of two or more.
  • a monohydric alcohol or a polyhydric alcohol is preferable.
  • the above monohydric alcohol is preferably one having 8 to 14 carbon atoms. If the number of carbon atoms is less than 8, volatility may increase, and if the number of carbon atoms exceeds 14, the effect of promoting absorption may decrease.
  • Such a monohydric alcohol is not particularly limited, and examples thereof include lauryl alcohol, oleyl alcohol, and cetyl alcohol.
  • the polyhydric alcohol is not particularly limited, and examples thereof include propylene glycol, 1,3-butanediol, glycerin, and polyethylene glycol.
  • the organic acid a monovalent organic acid or a polyvalent organic acid is preferable. Such organic acids are not particularly limited, and include, for example, monocarboxylic acids, dicarboxylic acids or salts thereof, and hydroxydicarboxylic acids or salts thereof.
  • the monocarboxylic acid as the organic acid is preferably one having 8 to 20 carbon atoms. If the number of carbon atoms is less than 8, the acidity is so strong that it may be difficult to apply to the human body. If the number of carbon atoms exceeds 20, the absorption promoting effect may be reduced.
  • Such a monocarboxylic acid is not particularly limited, and examples thereof include aliphatic monocarboxylic acids, nonanoic acid, caprylic acid, lauric acid, myristic acid, panolemitic acid, stearinic acid, and oleic acid. Carboxylic acids and the like can be mentioned.
  • the dicarboxylic acid or a salt thereof which is the organic acid, preferably has 2 to 8 carbon atoms. ⁇ If the prime number exceeds 8, the absorption promotion effect may be reduced.
  • Such dicarboxylic acids or salts thereof are not particularly limited, and include, for example, saturated aliphatic linear dicarboxylic acids such as oxalic acid, malonic acid, succinic acid, glutaric acid, pimelic acid, suberic acid, and adibic acid; Unsaturated aliphatic dicarboxylic acids such as fumaric acid and maleic acid Aromatic dicarboxylic acids such as phthalic acid, isophthalic acid and terephthalic acid; sodium salts, potassium salts, magnesium salts, calcium salts and aluminum salts thereof; No.
  • the above-mentioned hydroxydicarboxylic acid or a salt thereof as the above-mentioned organic acid preferably has 3 to 8 carbon atoms. When the number of carbon atoms exceeds 8, the absorption promoting effect may be reduced.
  • a hydroxydicarboxylic acid or a salt thereof is not particularly limited, and examples thereof include malic acid and tartaric acid; and salts thereof such as sodium salt, potassium salt, magnesium salt, calcium salt, and aluminum salt.
  • the higher fatty acid ester preferably has 11 to 36 carbon atoms. If the number of carbon atoms is less than 11, volatilization may easily occur, and if the number of carbon atoms exceeds 36, the absorption promotion effect may decrease.
  • Such higher fatty acid esters are not particularly limited, and include, for example, isopropyl myristate, isopropyl palmitate, isopropyl laurate, isopropyl stearate and the like.
  • the higher fatty acid ester can be obtained, for example, by reacting a higher fatty acid with an alcohol.
  • the higher fatty acid constituting the higher fatty acid ester is preferably one having 10 to 18 carbon atoms. When the number of carbon atoms is less than 10, the above-mentioned higher fatty acid ester as a product may be easily volatilized. When the number of carbon atoms exceeds 18, the transdermal absorption effect may be reduced.
  • Such higher fatty acids are not particularly limited, and include, for example, saturated aliphatic monocarboxylic acids such as capric acid, lauric acid, myristic acid, palmitic acid, and stearic acid; palmitoleic acid, oleic acid, Unsaturated aliphatic monocarboxylic acids such as vaccenic acid, linoleic acid, and linolenic acid; and saturated aliphatic dicarboxylic acids such as sebacic acid.
  • saturated aliphatic monocarboxylic acids such as capric acid, lauric acid, myristic acid, palmitic acid, and stearic acid
  • palmitoleic acid oleic acid
  • Unsaturated aliphatic monocarboxylic acids such as vaccenic acid, linoleic acid, and linolenic acid
  • saturated aliphatic dicarboxylic acids such as sebacic acid.
  • the alcohol constituting the higher fatty acid ester preferably has 1 to 18 carbon atoms. If the carbon number exceeds 18, the transdermal absorption effect may be reduced.
  • Such alcohols are not particularly restricted but include, for example, methyl alcohol, ethyl alcohol, propyl alcohol, isopropyl alcohol, butyl alcohol, isobutyl alcohol, pentino oleanol, hexino oleanol, heptyl alcohol, octyl alcohol, force prills alcohol, nonyl alcohol, particularly limited as decyl alcohol, lauryl alcohol, millimeter myristyl alcohol, Parumichi alcohol, c the hydroxycarboxylic acid ester aliphatic saturated alcohols and the like, such as stearyl alcohol Examples include myristyl lactate and cetyl lactate.
  • the above hydroxycarboxylic acid ester can be obtained, for example, by reacting hydroxycarboxylic acid with alcohol.
  • the hydroxycarboxylic acid constituting the hydroxycarboxylic acid ester preferably has 3 to 6 carbon atoms. If the number of carbon atoms is less than 3, the product hydroquinone carboxylate may be easily volatilized. If the number of carbon atoms exceeds 6, the transdermal absorption effect may be reduced.
  • Such hydroxycarboxylic acids are not particularly limited, and include, for example, monocarboxylic acids such as lactic acid and glyceric acid, malic acid, and dicarboxylic acids such as tartaric acid.
  • the alcohol constituting the above hydroquinone carboxylate is preferably an alcohol having 1 to 20 carbon atoms. If the carbon number exceeds 20, the transdermal absorption effect may decrease. Such alcohol is not particularly limited.
  • the above-mentioned alcohols and the like exemplified as those used in producing the higher fatty acid ester are exemplified.
  • the N-acyl sarcosine is not particularly limited, and includes, for example, N-lauroyl sarcosine, N-ylrail sarcosine, N-palmitoyl sarcosine, coconut oil fatty acid sarcosine and the like. Further, the sodium salt, potassium salt, magnesium salt, calcium salt, aluminum salt and the like of N-acylsarcosine can also be used.
  • any of a nonionic surfactant, an anionic surfactant, a surfactant, and an amphoteric surfactant can be used.
  • the nonionic surfactant is not particularly limited and includes, for example, sorbitan alkyl ethers such as sorbitan monolaurate and sorbitan mononoremitrate; polyoxyethylene (9) lauryl ether, polyoxyethylene (2) lauryl ether and the like. Polyoxyethylene alkyl ethers; fatty acid amides such as ethanoyl laurate; and polyoxoxylene fatty acid amides, alkyl amides, and the like.
  • the anionic surfactant is not particularly limited, and examples thereof include a surfactant having at least one selected from the group consisting of a carboxyl group, a sulfo group, a sulfate group, and a phosphate group.
  • a surfactant having a carboxyl group include fatty acid stones, ether carboxylic acids and salts thereof, and carboxylate salts such as condensates of amino acids and fatty acids.
  • the surfactant include an alkyl sulfonate, a sulfosuccinic acid, an ester sulfonate, an alkylaryl or an alkylnaphthalene sulfonate, and an N-acyl sulfonate.
  • Oiled oils, ester sulfates, ether sulfates, alkylaryl ether sulfates, amide sulfates, and the like are examples of surfactants having the above phosphate group. , Ether phosphates, alkylaryl phosphates and the like.
  • the cationic surfactant is not particularly limited, and examples thereof include fatty acid amines, alkyl quaternary ammonium salts, aromatic quaternary ammonium salts, pyridium salts, and imidium salts. Dazolym salts and the like.
  • amphoteric surfactant is not particularly limited, and examples thereof include carboquinbetaine such as betaine lauryldimethylaminoacetate, sulfobetaine, aminocarboxylate, and imidazoline derivative.
  • N-lauroylsarcosine, isopropyl myristate, and NO are particularly preferred as the transdermal absorption enhancer.
  • Isopropyl noremitate, fumaric acid, maleic acid, myristyl lactate, cetyl lactate, polyoxetylene (2) lauryl ether, polyquinethylene (9) lauryl ether, lauryl diethanolamide, polyhydric alcohol , Glycerin and propylene glycol are preferably used.
  • percutaneous absorption enhancer not only those exemplified above but also conventionally known ones can be used.
  • the content of the percutaneous absorption enhancer in the base is preferably 0.1 to 80 parts by weight, when the total amount of the base is 100 parts by weight. More preferably, it is 0.1 to 50 parts by weight.
  • the above-mentioned transdermal absorption enhancer itself can be used as a base.
  • a humectant In the percutaneous absorption external preparation of the present invention, a humectant, a viscosity modifier, an antioxidant, a pH adjuster, a preservative, a flavoring agent, a stabilizer, and the like may be further added to the base as necessary. It can also be added.
  • the external preparation for percutaneous absorption of the present invention can be composed of at least one base selected from the group consisting of ointments, creams, jelly, pastes, liniments, and lotions. That is, the external preparation for transdermal absorption of the present invention can be used as an ointment, cream, jelly, paste, liniment or lotion, or a combination of these forms.
  • the external preparation for transdermal absorption of the present invention is a transdermal absorption patch in which a pressure-sensitive adhesive layer is provided on one surface of a support, and the pressure-sensitive adhesive layer is composed of a base containing a drug. It can also be used as an external preparation for skin absorption.
  • the external preparation for transdermal absorption of the present invention can be prepared, for example, by providing a pressure-sensitive adhesive layer comprising the above-mentioned base containing methotrexate on one surface of a support, for example, It can be in the form of a star, tape, etc.
  • the support is appropriately selected according to the dosage form of the external preparation for transdermal absorption of the present invention (eg, cataplasm, blaster, tape, etc.).
  • a support is not particularly restricted but includes, for example, polyethylene, polypropylene, polyvinyl chloride, vinyl acetate-vinyl chloride copolymer, ethylene monovinyl acetate copolymer, ethylene monovinyl acetate carbon monoxide copolymer Resin films such as ethylene-butylacrylate carbon monoxide copolymer, polyvinylidene chloride, polyurethane, nylon, polyethylene terephthalate, polybutylene terephthalate; aluminum sheets, woven fabrics, non-woven fabrics, and laminated sheets of these And the like.
  • the pressure-sensitive adhesive constituting the pressure-sensitive adhesive layer is not particularly limited as long as it is pharmaceutically acceptable, and any conventionally known suitable pressure-sensitive adhesive can be used.
  • Adhesives, rubber-based adhesives, silicone-based adhesives, and urethane-based adhesives are preferably used. These may be used alone or in combination of two or more.
  • the properties of the pressure-sensitive adhesive when the pressure-sensitive adhesive is spread on the support it is possible to use appropriate properties such as a dissolution type, an emulsion type and a hot melt type.
  • the acryl-based pressure-sensitive adhesive includes a functional monomer and / or a polyfunctional monomer (b-2) copolymerizable with an alkyl (meth) acrylate (b-1) and an alkyl (meth) acrylate. It is preferably composed of a copolymer as a component.
  • the alkyl (meth) acrylate (b-1) is not particularly restricted but includes, for example, methyl (meth) acrylate, ethyl (meth) acrylate, butyl (meth) acrylate, 2-ethylhexyl (meth) acrylate, n-octyl (meth) acrylate, dodecyl (meth) acrylate, and the like. These may be used alone or in combination of two or more.
  • the alkyl (meth) acrylate (b-1) preferably has 4 to 12 carbon atoms in the alkyl group.
  • the number of carbon atoms is less than 4, the cohesive strength is improved, but the adhesive strength is reduced.
  • the number of carbon atoms exceeds 12, the adhesive strength may be improved, but the cohesive strength may be reduced.
  • the functional monomer is not particularly limited.
  • (meth) acrylic acid (meth) acrylic acid,
  • 2-Hydroxyquinethyl (meta) acrylate, 2-hydroxypropyl (meth) acrylate, glycidyl methacrylate, N-methylol (meth) acrylamide, N-butyne methyl Acrylamide and the like can be mentioned.
  • these functional monomers are copolymerized to form, for example, metal salts such as sodium hydroxide, calcium hydroxide, and aluminum hydroxide; isocyanate, epoxy resin, melamine resin, Crosslinking with a urea resin, ammonia, or the like can improve the cohesive strength of the pressure-sensitive adhesive.
  • the polyfunctional monomer is copolymerized to improve the cohesive strength of the pressure-sensitive adhesive.
  • the above-mentioned polyfunctional monomer is not particularly limited, and examples thereof include 1,6-hexane glycol dimethacrylate, tetraethylene glycol diacrylate, trimethylolpropane triacrylate, divinylbenzene, divinyltoluene, and diacyl.
  • Ril phthalate, diaryl maleate, diaryl diadipate, diaryl glycolate, triaryl isocyanurate, diethylene glycol bisaryl carbonate and the like can be mentioned.
  • acrylic pressure-sensitive adhesive those comprising the above-mentioned alkyl (meth) acrylate (b-1) and a copolymer containing a vinyl compound as a functional monomer as a monomer component are also preferable.
  • vinyl compounds are not particularly limited, and include, for example, butyl acetate, acrylonitrile, styrene, N-vinyl-1-pyrrolidone, and the like. Of these, N-vinyl-2-pyrrolidone is more preferred.
  • acrylic pressure-sensitive adhesives include, in particular, 55-95% by weight of 2-ethylhexyl acrylate, 5-45% by weight of N-vinyl-2-pyrrolidone, and the above-mentioned polyfunctional adhesives. It is preferable to use a copolymer comprising 0 to 0.5% by weight of a monomer having a monomer component.
  • acrylic pressure-sensitive adhesive one composed of a copolymer containing two or more kinds of the alkyl (meth) acrylates (b-1) as a monomer component is also preferable.
  • acryl-based adhesives include, in particular, 2-ethylhexyl acrylate. It is preferable to use a copolymer containing 5 to 30% by weight, dodecyl methacrylate 5 to 30% by weight, and a monomer component containing the above-mentioned polyfunctional monomer 0 to 0.5% by weight.
  • the acrylic pressure-sensitive adhesive has an alkyl (meth) acrylate as a main component, and the amounts of other components may be appropriately determined according to required performance.
  • the functional monomer is preferably copolymerized in an amount of 1 to 10% by weight in the acrylic pressure-sensitive adhesive, and the polyfunctional monomer is preferably copolymerized in an amount of 0 to 0.5% by weight.
  • the above-mentioned vinyl compound it is preferable that 50% by weight or less is copolymerized in the above-mentioned acrylic pressure-sensitive adhesive. More preferably, it is 1 to 40% by weight.
  • the acrylic pressure-sensitive adhesive may include, if necessary, inorganic fillers such as caic acid, zinc oxide and titanium oxide; plasticizers such as higher fatty acid esters; tackifiers such as ester gum; It may be added within.
  • inorganic fillers such as caic acid, zinc oxide and titanium oxide
  • plasticizers such as higher fatty acid esters
  • tackifiers such as ester gum
  • the rubber-based pressure-sensitive adhesive is obtained by adding a tackifier to rubber.
  • the rubber is not particularly limited, and examples thereof include natural rubber, styrene-butadiene rubber, polyisobutylene, styrene-isoprene-styrene block copolymer, styrene-butadiene-styrene block copolymer, and styrene-one-year-old styrene-styrene. And block copolymers.
  • the tackifier is not particularly limited, and includes, for example, rosin, hydrogenated rosin, rosin ester, terpene resin, terpene fuynol resin, petroleum resin, cumarone resin, cumarone-indene resin and the like.
  • a softening agent may be added to the rubber-based pressure-sensitive adhesive.
  • the above-mentioned denaturing agents are not particularly limited, and include, for example, armor oil, olive oil, camellia oil, Pacific oil, peanut oil, sesame oil, soybean oil, mink oil, cottonseed oil, corn oil, and safari oil. Oils such as mono-oil, coconut oil and castor oil; higher fatty acids such as oleic acid and lauric acid; liquid paraffin and polybutene.
  • any of the silicone-based pressure-sensitive adhesives conventionally used for pressure-sensitive adhesives for transdermal patches can be used, and is not particularly limited.
  • urethane-based adhesive it has been used in adhesives for transdermal patches Any of the urethane-based pressure-sensitive adhesives used can be used, and is not particularly limited.
  • the pressure-sensitive adhesive layer is preferably made of a pressure-sensitive adhesive containing at least one water-soluble polymer.
  • the water-soluble polymer is not particularly limited, and examples thereof include those containing a vinyl group, polysaccharides, and other water-soluble polymers.
  • the thing containing the vinyl group is not particularly limited, and examples thereof include polyacrylic acid, polyacrylate, and others.
  • examples of the above polyacrylate include monovalent metal salts of polyacrylic acid such as sodium polyacrylate and potassium polyacrylate; monoethanolamine polyacrylate, jetanolamine polyacrylate, triacrylate polyacrylate.
  • Amino salts of polyacrylic acid such as ethanolamine; and ammonium salts of polyacrylic acid.
  • Other examples of the above include, for example, polyvinyl alcohol, polyvinyl virolidone, polyvinyl ether, meth- oxyethylene-maleic anhydride copolymer, methacrylic acid polymer and the like.
  • the polysaccharides are not particularly limited, and include, for example, sodium alginate, ammonium alginate, carboxymethylcellulose, sodium carboquine methylcellulose, hydroxymethylcellulose, hydroxypropylcellulose, and hydroxyquinepropylethylcellulose. , Methylcellulose, soluble starch, carboxymethylamylose, dextrin and the like.
  • the other water-soluble polymers are not particularly limited, and include, for example, hemicelluloses such as pectin and agar powder; and plant gums such as gum arabic, tragacanth, and xanthan gum.
  • water-soluble polymer those having at least one selected from the group consisting of a carboxyl group, a hydroxyl group, and a salt thereof in the molecule are preferably used.
  • an acrylic acid polymer examples include acrylate polymer, maleic anhydride polymer, methacrylic acid polymer, carboxycellulose, polyvinyl alcohol, and hydroxycellulose.
  • those having a carboxyl group include polyacrylic acid, sodium polyacrylate, meth- oxyethylene-maleic anhydride copolymer, and styrene acrylate.
  • Copolymer acrylic acid-methacrylic acid amide copolymer, butyl acrylate-methacrylic acid copolymer, styrene-methacrylic acid copolymer, carboxyvinyl polymer, carboxymethylcellulose, sodium alginate and the like.
  • examples of those having a hydroxyl group include polyvinyl alcohol, hydroxymethyl cellulose, hydroxyquin propyl cellulose, and hydroxyquin propylethyl cellulose.
  • the water-soluble polymer can be used not only as a base of the pressure-sensitive adhesive layer but also as an additive of the acrylic pressure-sensitive adhesive, the rubber-based pressure-sensitive adhesive, the silicone-based pressure-sensitive adhesive, and the urethane-based pressure-sensitive adhesive. .
  • the external preparation for transdermal absorption of the present invention can be produced by a conventional method.
  • the base materials were manufactured by kneading, emulsifying, suspending, or dissolving the necessary base materials according to each dosage form. Thereafter, it can be produced by adding a drug, and if necessary, a transdermal absorption enhancer, other additives, and the like, and mixing with a commonly used kneader.
  • the production method varies depending on the type of the adhesive, but it is appropriately determined according to the dosage form (for example, plaster, tape, cataplasm, etc.). It can be manufactured by a conventional method such as hot melt type, solvent type and emulsion type.
  • Examples of the disease to be treated by the topical preparation for percutaneous absorption of the present invention include chronic inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, polymyositis and the like; leukemia, etc. Cancer diseases and the like.
  • Example 1
  • Test example 1 (Effect on rat adjuvant arthritis)
  • Example 1 and Comparative Examples 1 to 3 The effects on adjuvant arthritis of the external preparations and oral liquid preparations of Example 1 and Comparative Examples 1 to 3 were examined as follows. A 6-week-old male Lewis rat weighing 120 to 200 g was used as a test animal.
  • arthritis was induced by subcutaneously injecting 1 ml of MycobaccteriumumtubercculosiSHSTRACmgZmUO.1 suspended in flowing paraffin subcutaneously into the right hind leg of the rat. After the induction, an external preparation and an oral solution were administered as described below. After induction, to examine the degree of swelling of the right and left hind legs of the rat, the volume of the hind legs was measured before and after the induction of arthritis using Plethy smometer Cugo Bai 1e). The difference between the pre-challenge volume and the post-challenge volume was determined (this difference is shown in Table 1 as paw edema volume (m)).
  • Example 1 In the rat of the external preparation administration group of Example 1, the external preparation of Example 1 was applied to the shaved back skin for 2 days from the first day of each week at a rate of 0.1 g rat from the day of arthritis induction. Apply, cover with gauze (Kitakawa Sanitary Materials Co., Ltd.) from above, fix with elastic adhesive band (Silky Tex, product name of Alcare Co., Ltd.), peel off and remove on the third day After wiping off the adhering drug with gauze, the drug was closed on days 3-7. As a control for this test, the external preparation of Comparative Example 1 was administered in the same manner.
  • the oral liquid preparation of Comparative Example 2 was divided into three parts per week at a rate of 10 m1 Z kg Z1 from the induction of arthritis (that is, the first liquid of each week). , Twice daily (9: 00 and 17: 00), once on the second day (9: 00), and on days 3-7, the drug was discontinued. As a control for this test, the oral liquid preparation of Comparative Example 3 was administered in the same manner.
  • Table 1 shows the paw edema volumes (ml) as defined above, 14 days and 21 days after the day of arthritis induction.
  • Table 1 shows an average value of paw edema volume.
  • Example 2 As can be seen from Table 1, the degree of swelling of the left and right hind limbs was significantly suppressed in the topical drug administration group of Example 1 compared to the topical drug administration group of Comparative Example 1, and the degree of the suppression was compared with Comparative Example 2. The degree of suppression was equal to or greater than that of the oral solution administration group of Comparative Example 3 and the oral solution administration group of Comparative Example 3. Met. That is, the external preparation for transdermal absorption of the present invention had remarkable inhibitory activity against chronic inflammatory diseases. Next, the external preparations and oral liquid preparations of Example 2 and Comparative Examples 1, 3 and 4 below were prepared, and the obtained external preparations and oral liquid preparations suppressed the immune inflammatory reaction (the effect on the rat tuberculin reaction). Was tested. Example 2
  • Metriclexate manufactured by Wako Pure Chemical Industries, Ltd. 100 mg, sodium carboxymethylcellulose sodium (manufactured by Wako Pure Chemical Industries, Ltd.) 500 mg and purified water 100 ml are weighed and thoroughly stirred. A homogeneous oral solution was prepared.
  • Test Example 2 (Effect on la sototuberculin reaction)
  • tuberculin reaction which is an immune inflammatory reaction that causes chronic inflammatory diseases
  • the external preparations and oral liquids of Example 2 and Comparative Examples 1, 3, and 4 were used as test substances. The effect on tuberculin response was tested.
  • Wistar male rats weighing 170-250 g were used as test animals.
  • the specific test procedure was as follows.
  • Example 2 In the rat of the external preparation administration group of Example 2, the external preparation of Example 2 was applied to the shaved back skin at a rate of 0.1 g Z rat two days before induction, and gauze (Kitakawa Sanitary) was applied from above. (Made by Material Co., Ltd.), and then fixed with a non-sticky adhesive pad (manufactured by Alcare Inc., trade name: Silky Tex). Before induction 1, the gauze, elastic adhesive band and external preparation were separated, and the external preparation remaining on the skin was removed with absorbent cotton. The external preparation of Comparative Example 1 was administered in the same manner as a control for this test.
  • the oral solution in Comparative Example 4 was orally administered at a ratio of 10 m1Zkg two days before the induction.
  • the oral liquid preparation of Comparative Example 3 was orally administered in the same manner.
  • the erythema intensity at the reaction induction site was measured according to the criteria of Draise, and then the skin of the reaction part was punched out with a punch having a diameter of 8 cm, and the skin weight was measured.
  • This test was performed using 5 rats each, and the erythema intensity and skin weight were determined by averaging ⁇ obtained for these rats.
  • Table 2 shows the test results.
  • Example 2 In order to examine the persistence of the action on the rat tuberculin reaction, the effect on the rat tuberculin reaction was tested using the external preparations and oral liquid preparations of Example 2 and Comparative Examples 1, 3, and 4 as test substances.
  • test animal As a test animal, a male male rat weighing 180 to 230 g was used.
  • the specific test procedure was as follows.
  • Example 2 In the rat of the external preparation administration group of Example 2, the external preparation of Example 2 was applied to the shaved back skin at a rate of 0.1 g / rat 4, 4, 2, 1 day before or at the time of induction. After covering with gauze (made by Kitagawa Sanitary Materials Co., Ltd.) from above, it was fixed with an elastic adhesive band (manufactured by Alcare, trade name Silky Tex). On the next day, the gauze, the elastic adhesive band and the external preparation were separated, and the external preparation remaining on the skin was removed with absorbent cotton. The external preparation of Comparative Example 1 was administered in the same manner as a control in this test.
  • gauze made by Kitagawa Sanitary Materials Co., Ltd.
  • the oral solution of Comparative Example 4 was orally administered at a rate of 10 m 1 g before or at the time of induction 4, 3, 2, or 1.
  • the oral liquid preparation of Comparative Example 3 was orally administered in the same manner. Twenty-four hours after the induction, the skin of the reaction site was punched out with a punch having a diameter of 8 cm, and the skin weight was measured.
  • This test was performed using 5 rats each, and the skin weight was the average of the values obtained for these rats.
  • Table 3 shows the test results.
  • Example 3 As is evident from Table 3, it was found that the effect of the topical preparation of Example 2 lasted longer than that of the group of oral liquid preparation of Comparative Example 4. That is, the external preparation for percutaneous absorption of the present invention had an excellent persistence in the effect on the immune inflammatory reaction that causes chronic inflammatory diseases.
  • the external preparations and oral liquid preparations of Example 2 and Comparative Example 4 were prepared, and a rat blood concentration measurement test of the obtained external preparations and oral liquid preparations was performed.
  • Test example 4 (rat blood kinetic measurement test)
  • Example 2 As a test animal, a Wistar male rat weighing 170.250 g was used. In the rat of the external preparation administration group of Example 2, the external preparation of Example 2 was applied to the shaved back skin at a rate of 0.1 lat and covered with gauze (made by Kitagawa Sanitary Materials Co., Ltd.) from above. After that, fix it with an elastic adhesive band (manufactured by Alcare, Silky Tex) o
  • the oral solution of Comparative Example 4 was orally administered at a rate of 10 ml / kg.
  • Example 3 As can be seen from Table 4, in the group to which the external preparation of Example 2 was administered, the continuation of the blood concentration was observed as compared with the group to which the oral liquid preparation of Comparative Example 4 was administered. This result supports the persistence of the rat-tuberculin reaction.
  • Example 3 As can be seen from Table 4, in the group to which the external preparation of Example 2 was administered, the continuation of the blood concentration was observed as compared with the group to which the oral liquid preparation of Comparative Example 4 was administered. This result supports the persistence of the rat-tuberculin reaction.
  • Example 3 As can be seen from Table 4, in the group to which the external preparation of Example 2 was administered, the continuation of the blood concentration was observed as compared with the group to which the oral liquid preparation of Comparative Example 4 was administered. This result supports the persistence of the rat-tuberculin reaction.
  • Wistar male rats weighing 170-250 g were used as test animals.
  • the external preparations of Examples 3 and 4 were applied to the shaved back skin at a rate of 0.1 g Z rat, and gauze (Kitakawa Sanitary) was applied from above. After that, it was fixed with an elastic adhesive band (manufactured by Alcare, trade name: Silky Tex). On the next day, the gauze, the elastic adhesive band and the external preparation were separated, and the external preparation remaining on the skin was removed with absorbent cotton. As a control for this test, the external preparation of Comparative Example 1 was administered in the same manner.
  • the oral solution of Comparative Example 5 was orally administered at a rate of 10 ml / kg.
  • the oral liquid preparation of Comparative Example 3 was administered in the same manner.
  • Table 5 shows the average value of leukocyte change.
  • EHA 2-ethylhexyl acrylate
  • VP N-vinyl-1-pyrrolidone
  • the methotrexate was suspended in ethyl acetate, and the solid content (the sum of the polymer after drying the ethyl acetate and the methotrexate) was 30% by weight. Replacement paper (Rule 26) In addition, the mixture was added so that the methotrexate concentration in the solid content was 0.5% by weight, and the mixture was stirred and mixed.
  • PET polyethylene terephthalate
  • Example 7 An external preparation for transdermal absorption was prepared in the same manner as in Example 5, except that the content of methotrexate in the solid content was changed to 5% by weight.
  • a percutaneous absorption external preparation was prepared in the same manner as in Example 5 except that the content of methotrexate in the solid content was changed to 10% by weight, and the adhesive surface was treated with an acrylic gel (Sekisui Resin).
  • the product was bonded to a trade name, Technogel CR), and cut into a circle having an area of 3.14 cm 2 to prepare a transdermal absorption external preparation.
  • Example 8
  • Emulsion of polymer (acrylic acid-n-butyl acrylate, manufactured by ROHM 'And'Haas' Japan, trade name N-580) 8 g of methotrexate 0.02 g, After adding 4 g of distilled water and mixing with stirring, the solution was siliconized. On a 35 m-thick PET film so that the thickness after drying is about 100 ⁇ m, and then, after adhering a 35 / zm-thick PET film, 3. Cut into a circular shape of 14 cm 2 to prepare a transdermal absorption external preparation.
  • Test Example 6 (Lat skin captive permeability test)
  • the diffusion cell shown in FIG. 1 was prepared.
  • the diffusion cell 1 is formed by a bottomed cylindrical receptor tank 2 and a bottomed cylindrical donor vessel 3 arranged on the receptor tank 2.
  • An opening 4 is provided in the center of the bottom wall of the donner tank 3, the bottom wall extends in the peripheral direction, and a flange 5 is provided.
  • a flange 6 is provided at the upper part of the receptor tank 2, and a laterally protruding sample ring 7 is attached to the side wall.c
  • the flange 5 and the flange 6 are overlapped so as to face each other. Are airtightly and concentrically stacked. Further, a magnet stirrer 9 is placed inside the receptor tank 2.
  • Wistar male rats weighing 170-250 g were used as test animals.
  • the tissue and muscle layer were removed to obtain a captive piece 8 of approximately 5 cm x 5 cm.
  • the obtained skin piece 8 was attached between the flange 5 and the flange 6 of the diffusion cell 1, and the opening 4 of the donor vessel 3 was completely closed with the skin piece 8.
  • the external preparations of Examples 1 and 5 to 7 shown above were applied to the central portion 10 of the skin piece 8 so as to be in contact with the skin piece 8.
  • the external preparation of Example 1 was prepared by uniformly applying 0.1 g to one surface of a circular (area of 3.14 cm 2 ) polyethylene terephthalate and contacting the skin piece 8 with the skin piece 8. It was affixed to the center 10 of 8.
  • Receptor tank 2 was filled with the receptor liquid, placed in a thermostat maintained at 37 ° C., and stirred by rotating magnet stirrer 9 with a magnet stirring device. 18 and 24 hours after the start of the test, 1 ml of the receptor solution was sampled from the sampling port 7, and 1 ml of the fresh receptor solution was replenished instead. Drugs that have permeated the skin are dissolved in the collected receptor solution. The drug concentration in the collected receptor solution was measured by high performance liquid chromatography, and the drug permeation amount (unit: Ug / cm 2 ) was calculated.
  • Receptor fluid adjustment method in distilled water, N a H 2 P 0 4 5 x 1 0- 4 M, N a 2 HP 0 4 2 X 1 0- 4 M, NaC l l. 5 X 1 0 and, in a buffer containing sulfuric acid Gentama leucine 1 0 ⁇ g / m 1, by adding 1 N-N a OH solution PH was adjusted to 7.2.
  • the external preparation for percutaneous absorption of the present invention has the above-mentioned constitution, and is effective for chronic inflammatory diseases such as autoimmune diseases (for example, rheumatoid arthritis) and cancer diseases such as leukemia. is there. In other words, it has a systemic therapeutic effect on these diseases, continuously exerts effective drug effects, can reduce the side effects seen in oral drugs, etc. And improvement of quality, quality, life, etc. can be achieved.
  • chronic inflammatory diseases such as autoimmune diseases (for example, rheumatoid arthritis) and cancer diseases such as leukemia.
  • autoimmune diseases for example, rheumatoid arthritis
  • cancer diseases such as leukemia.
  • it has a systemic therapeutic effect on these diseases, continuously exerts effective drug effects, can reduce the side effects seen in oral drugs, etc. And improvement of quality, quality, life, etc. can be achieved.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur des préparations de méthotréxate à absorption percutanée dotées d'effets thérapeutiques systémiques sur des maladies inflammatoires chroniques telles que les maladies auto-immunes (polyarthrite rhumatoïde, etc.) et les cancers tels que la leucémie, et tendant à soulager les effets secondaires du méthotréxate, et à améliorer l'observance et la qualité de vie des patients. Lesdites préparations, qui contiennent du méthotréxate dans leurs bases, exercent des effets thérapeutiques systémiques sur les patients.
PCT/JP1998/000123 1997-01-16 1998-01-16 Preparations a usage externe a absorption percutanee WO1998031369A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU54957/98A AU5495798A (en) 1997-01-16 1998-01-16 External preparations for percutaneous absorption

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP551697 1997-01-16
JP9/5516 1997-01-16
JP9/72294 1997-03-25
JP7229497 1997-03-25
JP34799997 1997-12-17
JP9/347999 1997-12-17

Publications (1)

Publication Number Publication Date
WO1998031369A1 true WO1998031369A1 (fr) 1998-07-23

Family

ID=27276790

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1998/000123 WO1998031369A1 (fr) 1997-01-16 1998-01-16 Preparations a usage externe a absorption percutanee

Country Status (2)

Country Link
AU (1) AU5495798A (fr)
WO (1) WO1998031369A1 (fr)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013512898A (ja) * 2009-12-02 2013-04-18 ニンブル エピテック リミテッド ライアビリティ カンパニー 低メチル化剤及びヒストン脱アセチル化酵素阻害剤を含む薬学的組成物
US8480631B2 (en) 2009-03-20 2013-07-09 Antares Pharma, Inc. Hazardous agent injection system
US8915889B2 (en) 2008-08-05 2014-12-23 Antares Pharma, Inc. Multiple dosage injector
US9144648B2 (en) 2006-05-03 2015-09-29 Antares Pharma, Inc. Injector with adjustable dosing
US9180259B2 (en) 2005-01-24 2015-11-10 Antares Pharma, Inc. Prefilled syringe jet injector
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
US9278952B2 (en) 2013-03-06 2016-03-08 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine H4 receptor
US9333309B2 (en) 2002-02-11 2016-05-10 Antares Pharma, Inc. Intradermal injector
US9364611B2 (en) 2012-05-07 2016-06-14 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
US9446195B2 (en) 2011-07-15 2016-09-20 Antares Pharma, Inc. Injection device with cammed ram assembly
US9486583B2 (en) 2012-03-06 2016-11-08 Antares Pharma, Inc. Prefilled syringe with breakaway force feature
US9707354B2 (en) 2013-03-11 2017-07-18 Antares Pharma, Inc. Multiple dosage injector with rack and pinion dosage system
US9744302B2 (en) 2013-02-11 2017-08-29 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
US9808582B2 (en) 2006-05-03 2017-11-07 Antares Pharma, Inc. Two-stage reconstituting injector
US9867949B2 (en) 2008-03-10 2018-01-16 Antares Pharma, Inc. Injector safety device
US9950125B2 (en) 2012-04-06 2018-04-24 Antares Pharma, Inc. Needle assisted jet injection administration of testosterone compositions
WO2018124281A1 (fr) * 2016-12-28 2018-07-05 富山化学工業株式会社 Composition topique
US10675400B2 (en) 2013-03-12 2020-06-09 Antares Pharma, Inc. Prefilled syringes and kits thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6327432A (ja) * 1986-05-30 1988-02-05 ザ　リ−ジエンツ　オブ　ザ　ユニバ−シテイ　オブ　カリフオルニア 高増殖性上皮疾患の治療のための局部的なメトトレキセ−ト調製物およびそれを用いた高増殖性上皮疾患の治療方法
WO1998003641A1 (fr) * 1996-07-23 1998-01-29 Crandall Wilson T Transport transdermique de molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6327432A (ja) * 1986-05-30 1988-02-05 ザ　リ−ジエンツ　オブ　ザ　ユニバ−シテイ　オブ　カリフオルニア 高増殖性上皮疾患の治療のための局部的なメトトレキセ−ト調製物およびそれを用いた高増殖性上皮疾患の治療方法
WO1998003641A1 (fr) * 1996-07-23 1998-01-29 Crandall Wilson T Transport transdermique de molecules

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9333309B2 (en) 2002-02-11 2016-05-10 Antares Pharma, Inc. Intradermal injector
US9737670B2 (en) 2002-02-11 2017-08-22 Antares Pharma, Inc. Intradermal injector
US9180259B2 (en) 2005-01-24 2015-11-10 Antares Pharma, Inc. Prefilled syringe jet injector
US9629959B2 (en) 2005-01-24 2017-04-25 Antares Pharma, Inc. Prefilled syringe jet injector
US10478560B2 (en) 2005-01-24 2019-11-19 Antares Pharma, Inc. Prefilled syringe injector
US11446441B2 (en) 2005-01-24 2022-09-20 Antares Pharma, Inc. Prefilled syringe injector
US11471600B2 (en) 2006-05-03 2022-10-18 Antares Pharma, Inc. Injector with adjustable dosing
US9144648B2 (en) 2006-05-03 2015-09-29 Antares Pharma, Inc. Injector with adjustable dosing
US10688250B2 (en) 2006-05-03 2020-06-23 Antares Pharma, Inc. Two-stage reconstituting injector
US12121704B2 (en) 2006-05-03 2024-10-22 Antares Pharma, Inc. Injector with adjustable dosing
US9808582B2 (en) 2006-05-03 2017-11-07 Antares Pharma, Inc. Two-stage reconstituting injector
US10543316B2 (en) 2006-05-03 2020-01-28 Antares Pharma, Inc. Injector with adjustable dosing
US11547808B2 (en) 2006-05-03 2023-01-10 Antares Pharma, Inc. Two-stage reconstituting injector
US10709844B2 (en) 2008-03-10 2020-07-14 Antares Pharma, Inc. Injector safety device
US11684723B2 (en) 2008-03-10 2023-06-27 Antares Pharma, Inc. Injector safety device
US9867949B2 (en) 2008-03-10 2018-01-16 Antares Pharma, Inc. Injector safety device
US10300212B2 (en) 2008-08-05 2019-05-28 Antares Pharma, Inc. Multiple dosage injector
US11058824B2 (en) 2008-08-05 2021-07-13 Antares Pharma, Inc. Multiple dosage injector
US8915889B2 (en) 2008-08-05 2014-12-23 Antares Pharma, Inc. Multiple dosage injector
US9750881B2 (en) 2009-03-20 2017-09-05 Antares Pharma, Inc. Hazardous agent injection system
US10555954B2 (en) 2009-03-20 2020-02-11 Antares Pharma, Inc. Hazardous agent injection system
US11497753B2 (en) 2009-03-20 2022-11-15 Antares Pharma, Inc. Hazardous agent injection system
US8480631B2 (en) 2009-03-20 2013-07-09 Antares Pharma, Inc. Hazardous agent injection system
US8579865B2 (en) 2009-03-20 2013-11-12 Antares Pharma, Inc. Hazardous agent injection system
US8945063B2 (en) 2009-03-20 2015-02-03 Antares Pharma, Inc. Hazardous agent injection system
JP2013512898A (ja) * 2009-12-02 2013-04-18 ニンブル エピテック リミテッド ライアビリティ カンパニー 低メチル化剤及びヒストン脱アセチル化酵素阻害剤を含む薬学的組成物
US10434090B2 (en) 2009-12-02 2019-10-08 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
US12179007B2 (en) 2011-07-15 2024-12-31 Antares Pharma, Inc. Injection device with cammed ram assembly
US11185642B2 (en) 2011-07-15 2021-11-30 Antares Pharma, Inc. Injection device with cammed ram assembly
US10279131B2 (en) 2011-07-15 2019-05-07 Antares Pharma, Inc. Injection device with cammed RAM assembly
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
US9446195B2 (en) 2011-07-15 2016-09-20 Antares Pharma, Inc. Injection device with cammed ram assembly
US10568809B2 (en) 2011-07-15 2020-02-25 Ferring B.V. Liquid-transfer adapter beveled spike
US9486583B2 (en) 2012-03-06 2016-11-08 Antares Pharma, Inc. Prefilled syringe with breakaway force feature
US10478559B2 (en) 2012-03-06 2019-11-19 Antares Pharma, Inc. Prefilled syringe with breakaway force feature
US11602597B2 (en) 2012-03-06 2023-03-14 Antares Pharma, Inc. Prefilled syringe with breakaway force feature
US9950125B2 (en) 2012-04-06 2018-04-24 Antares Pharma, Inc. Needle assisted jet injection administration of testosterone compositions
US11771646B2 (en) 2012-04-06 2023-10-03 Antares Pharma, Inc. Needle assisted jet injection administration of testosterone compositions
US10821072B2 (en) 2012-04-06 2020-11-03 Antares Pharma, Inc. Needle assisted jet injection administration of testosterone compositions
US10905827B2 (en) 2012-05-07 2021-02-02 Antares Pharma, Inc. Injection device with cammed ram assembly
US9364610B2 (en) 2012-05-07 2016-06-14 Antares Pharma, Inc. Injection device with cammed ram assembly
US10357609B2 (en) 2012-05-07 2019-07-23 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
US11446440B2 (en) 2012-05-07 2022-09-20 Antares Pharma, Inc. Needle assisted injection device having reduced trigger force
US12220560B2 (en) 2012-05-07 2025-02-11 Antares Pharma, Inc. Needle assisted injection device having reduced trigger force
US12171986B2 (en) 2012-05-07 2024-12-24 Antares Pharma, Inc. Injection device with cammed ram assembly
US9364611B2 (en) 2012-05-07 2016-06-14 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
US11813435B2 (en) 2013-02-11 2023-11-14 Antares Pharma, Inc. Needle assisted injection device having reduced trigger force
US10881798B2 (en) 2013-02-11 2021-01-05 Antares Pharma, Inc. Needle assisted injection device having reduced trigger force
US9744302B2 (en) 2013-02-11 2017-08-29 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
US9278952B2 (en) 2013-03-06 2016-03-08 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine H4 receptor
US9707354B2 (en) 2013-03-11 2017-07-18 Antares Pharma, Inc. Multiple dosage injector with rack and pinion dosage system
US11628260B2 (en) 2013-03-11 2023-04-18 Antares Pharma, Inc. Multiple dosage injector with rack and pinion dosage system
US10610649B2 (en) 2013-03-11 2020-04-07 Antares Pharma, Inc. Multiple dosage injector with rack and pinion dosage system
US10675400B2 (en) 2013-03-12 2020-06-09 Antares Pharma, Inc. Prefilled syringes and kits thereof
JP7176957B2 (ja) 2016-12-28 2022-11-22 富士フイルム富山化学株式会社 外用組成物
JPWO2018124281A1 (ja) * 2016-12-28 2019-10-31 富士フイルム富山化学株式会社 外用組成物
WO2018124281A1 (fr) * 2016-12-28 2018-07-05 富山化学工業株式会社 Composition topique

Also Published As

Publication number Publication date
AU5495798A (en) 1998-08-07

Similar Documents

Publication Publication Date Title
WO1998031369A1 (fr) Preparations a usage externe a absorption percutanee
JP3273430B2 (ja) エストロゲン含有ゲル製剤
CZ302169B6 (cs) Transdermální terapeutický systém s neutralizovanými akrylátovými adhezivními lepidly
US5252588A (en) Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation
WO2006082728A1 (fr) Patch d’absorption transdermique
JP6336476B2 (ja) ホルモン及びその他の薬剤を経皮送達するための組成物及び方法
GB2273044A (en) Medicinal patches for percutaneous administration
EP2062575A1 (fr) Préparation adhésive
AU2007200426A1 (en) Transdermal delivery of lasofoxifene
KR20000065244A (ko) 알즈하이머 질환 치료용 경피 투여 프로펜토필린 조성물
KR930007407B1 (ko) 경피흡수성 에페리손 또는 톨페리손 제제
JP4851671B2 (ja) トラニラスト経皮吸収貼付剤およびその製造方法
JPS63104913A (ja) 外用貼付剤
JP3255717B2 (ja) 経皮吸収製剤
US20140370077A1 (en) Transdermal drug delivery system containing fentanyl
JP3002493B2 (ja) 経皮吸収製剤
JPH11193235A (ja) 経皮吸収外用剤
JP5389824B2 (ja) 尿素成分を有する経皮治療システム
JP3295735B2 (ja) エストリオール経皮投与貼付剤
JPH111435A (ja) 経皮吸収外用剤
US20250082584A1 (en) Transdermal therapeutic system for the transdermal administration of selexipag
JP2823700B2 (ja) 望ましくない陣痛作用の抑制、早産の抑制及び陣痛作用の調整のための経皮投与形の医薬品
WO1999030702A1 (fr) Preparation a base de levodopa absorbable par voie percutanee
JPH0344327A (ja) 経皮吸収製剤
JPH11335281A (ja) 皮膚疾患治療用外用剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN JP KR RU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载